Evidence map›Paper›PMID 34217773›Full record

Observational studyDiabetes research and clinical practice2021

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study.

Gottfried Rudofsky, Andrei-Mircea Catarig, Lucie Favre, Katrine Grau, Susan Häfliger, Robert Thomann, Bernd Schultes

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Diabetes research and clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03631186. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03631186 completed

SURE SWITZERLAND: A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes

Ran2018Enrolled215Registered outcomes18Posted comparisons0ConditionsDiabetes Mellitus, Type 2Armssemaglutide
Open the trial in the graph
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024 · on this map
    Article
  9. Article
  10. Article
  11. Observational
  12. Observational
  13. Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2023
    Observational
  14. Observational
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Gottfried RudofskyCantonal Hospital Olten, Clinic of Endocrinology and Metabolic Diseases, Olten, Switzerland. Electronic address: gottfried.rudofsky@spital.so.ch.
Andrei-Mircea CatarigNovo Nordisk A/S, Søborg, Denmark.
Lucie FavreDivision of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital, Lausanne, Switzerland.
Katrine GrauNovo Nordisk A/S, Søborg, Denmark.
Susan HäfligerNovo Nordisk Pharma AG, Zürich, Switzerland.
Robert ThomannStoffwechselzentrum BSS, Solothurn, Switzerland.
Bernd SchultesMetabolic Center St. Gallen, St. Gallen, Switzerland.
Novo Nordisk (Denmark) · DKKantonsschule Olten · CHNovo Nordisk (Switzerland) · CHSchweizerische Ärztegesellschaft für Psycholytische Therapie · CHUniversity of Lausanne · CHUniversity of St. Gallen · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsSURE Switzerland (NCT03631186) investigated real-world once-weekly (OW) semaglutide use in adults with type 2 diabetes (T2D).

methodsThis multicentre, prospective, observational study enrolled adults with T2D with ≥ 1 documented HbA

resultsOverall, 214 patients initiated semaglutide (baseline HbA

conclusionsPatients with T2D in Switzerland initiating OW semaglutide experienced clinically relevant glycaemic control and BW improvements in a real-world setting, supporting semaglutide use in routine clinical practice.

Indexed as

Diabetes Mellitus, Type 2AdultGlucagon-Like PeptidesGlycated HemoglobinHumansHypoglycemic AgentsProspective StudiesSemaglutideSwitzerlandGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsSemaglutideGlucagon-like peptide-1 receptor agonistGlucose controlReal-world evidenceSemaglutideSURE studyType 2 diabetes

Identifiers

PMID34217773
OpenAlexW3182602136

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.